FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARAWAVE NAV Pulsed Field Ablation C
Farapulse, Inc. · Decision date Jan 12, 2026
What did the FDA approve?
FDA records P230030/S012 as a supplement to PMA P230030, with the supplement type “Panel Track”. The recorded decision is approval, dated Jan 12, 2026.
FDA approval order statement
for the FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARAWAVE NAV Pulsed Field Ablation Catheter, FARAPOINT Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable, FARASTAR Pulsed Field Ablation Generator, FARASTAR Recording System Module, FARASTAR Mapping System Module, FARASTAR Stimulation Module Cable, FARASTAR EGM Cable, FARASTAR Stimulation Module Male Cable, FARASTAR Stimulation Module Female Cable, FARASTAR Stimulation Module Y-Cable Long, FARASTAR Stimulation Module Y-Cable Short, FARASTAR Recording System Module Catheter Pin Cable, FARASTAR Recording System Module ECG Trunk Cable, FARASTAR Recording System Module ECG Output Module (AAMI/IEC), FARASTAR Recording System Module EGM Input Module, FARASTAR SNAP CABLE R/L (AAMI/IEC), FARASTAR SNAP CABLE V SET (AAMI), FARASTAR SNAP CABLE C SET (IEC), FARASTAR Recording System Module ECG Output to Rhythmia HDx ECG Input Cable, FARASTAR Recording System Module EGM Output to Rhythmia HDx EGM Input Cable, FARASTAR Mapping System Module Back Patch Cable, FARASTAR Mapping System Module Back Patch Cable Male, FARASTAR Mapping System Module BNC BNC-Phono Cable, FARASTAR Mapping System Module Rhythmia ABL Cable, FARASTAR Mapping System Module Auxiliary Cable, FARASTAR EGM to EP Recording System Cable FARAPOINT) to add the FARAPOINT Pulsed Field Ablation Catheter and the FARASTAR EGM to EP Recording System Cable. This device is indicated for:FARAWAVE and FARAWAVE NAV Pulsed Field Ablation CathetersThe FARAWAVE Catheter is indicated for: the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic Paroxysmal Atrial Fibrillation (PAF). the isolation of pulmonary veins and the posterior wall in the treatment of drug-refractory, symptomatic Persistent Atrial Fibrillation (episode duration less than one year).FARAPOINT Pulsed Field Ablation CatheterThe FARAPOINT Catheter is indicated for use as an adjunctive device for the creation of an ablation line between the inferior vena cava and the tricuspid valve when any FARAWAVE Catheter is used in the endocardial treatment of drug resistant, symptomatic persistent atrial fibrillation (episode duration no greater than 12 months).FARASTAR Pulsed Field Ablation GeneratorThe FARASTAR PFA Generator is intended for use with a compatible Boston Scientific PFA catheter in cardiac ablation procedures.FARASTAR Recording System ModuleThe FARASTAR Recording System Module (RSM) is indicated for use in an electrophysiology lab environment, as a filtering/protection unit to be connected between the patient and any attached recording systems and/or ECG systems, and as an interface for cardiac stimulation output.FARASTAR Catheter Connection CableThe FARASTAR Connection Cable is intended to be used with a FARAPULSE Catheter during an Electrophysiology procedure for cardiac tissue ablation.
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Cardiovascular
- Decision date
- Jan 12, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P230030/S012
- Regulatory pathway
- PMA supplement
- Applicant
- Farapulse, Inc.
- Product code
- QZI
- Decision code
- APPR
- Decision date
- Jan 12, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Farapulse, Inc.
- Product code
- QZI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230030. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230030 · Original PMA
FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,
P230030/S012 received
Application receipt date recorded by FDA.
P230030/S015 · Related supplement
FARAPULSE Pulsed Field Ablation System
P230030/S014 · Related supplement
FARAPULSE Pulsed Field Ablation System
P230030/S013 · Related supplement
FARASTAR Pulsed Field Ablation (PFA) Generator; FARASTAR Mapping System Module (MSM); FARASTAR Recording System Modul
P230030/S012 · FDA decision
Panel Track
P230030/S017 · Related supplement
FARAPULSE Pulsed Field Ablation System (FARAPULSE)
P230030/S019 · Related supplement
FARAPULSE Pulsed Field Ablation System
P230030/S021 · Related supplement
FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,
P230030/S023 · Related supplement
FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,
P230030/S022 · Related supplement
FARAPULSE Pulsed Field Ablation System (FARAPULSE)
P230030/S018 · Related supplement
FARAPULSE Pulsed Field Ablation System
P230030/S016 · Related supplement
FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,
P230030/S024 · Related supplement
FARASTAR Pulsed Field Ablation (PFA) Generator; FARASTAR Mapping System Module (MSM); FARASTAR Recording System Modul
P230030/S025 · Related supplement
FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation Catheter, FARASTAR Catheter Connection Cable,
Timeline entries are records held by MedtechLedger for P230030. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230030
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Farapulse, Inc. | PMA approval | Jan 30, 2024 | FDA | |
FARAPULSE Pulsed Field Ablation SystemP230030/S015 | Farapulse, Inc. | PMA supplement | Aug 12, 2025 | FDA |
FARAPULSE Pulsed Field Ablation SystemP230030/S014 | Farapulse, Inc. | PMA supplement | Aug 14, 2025 | FDA |
| Farapulse, Inc. | PMA supplement | Sep 24, 2025 | FDA | |
| Farapulse, Inc. | PMA supplement | Jan 13, 2026 | FDA | |
FARAPULSE Pulsed Field Ablation SystemP230030/S019 | Farapulse, Inc. | PMA supplement | May 6, 2026 | FDA |
| Farapulse, Inc. | PMA supplement | Jun 5, 2026 | FDA | |
| Farapulse, Inc. | PMA supplement | Jun 26, 2026 | FDA | |
| Farapulse, Inc. | PMA supplement | Jul 10, 2026 | FDA | |
FARAPULSE Pulsed Field Ablation SystemP230030/S018 | Farapulse, Inc. | PMA supplement | Aug 6, 2026 | FDA |
| Farapulse, Inc. | PMA supplement | Aug 25, 2026 | FDA | |
| Farapulse, Inc. | PMA supplement | Sep 4, 2026 | FDA | |
| Farapulse, Inc. | PMA supplement | Oct 2, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Farapulse, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3715 Haven Ave., Suite 110, Menlo Park, CA, 94025
Sources and methodology
- Original FDA record: P230030/S012
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






